Nanocyclo (cyclosporine) / Immune Pharma - LARVOL DELTA

Treatment Outcomes for up to 2 Years in Patients Aged Less Than 12 Years with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis: Real-World Data From PEDISTAD (ACD-ASM 2023) - P=N/A | N= 161 | NCT03849716 | Sponsor: Sanofi | "144 patients received dupilumab (mean treatment observation period: 9.4 months), 114 received methotrexate (13.7 months), 121 received cyclosporine (11.8 months). The most common baseline type 2 inflammatory comorbidities were food allergies (dupilumab: 54.2%, methotrexate: 43.2%) and allergic rhinitis (cyclosporine: 42.5%)....AE rates were 18.1% dupilumab, 29.8% methotrexate, and 31.4% cyclosporine whilst accumulated 2-year discontinuation rates were 8.3% for dupilumab, 28.9% for methotrexate and 43.0% for cyclosporine."

Psoriasis vs. Eczema: Differences, Images, Treatment - "Eczema and psoriasis, while two distinct conditions, have something key in common. Both these diseases, says Dr. Amy Paller...Dr. Paller explained that eczema is usually 'characterized by poorly demarcated red, dry areas with fine scale,' while psoriasis appears as 'red, well-circumscribed lesions (called plaques) with heaped-up, white scaling.'"

Media quote • Psoriasis

Translating Psoriasis Guidelines into Practice - "Before we dive into our discussion, let's outline the Guideline-Based Approach to Treatment Selection....Dr. Armstrong recommends a 'proactive approach' in topical treatments. Once patients have treated psoriasis flares and maintained clearance, it is important to continue treatment of these clinically quiescent areas."

Media quote

Pediatric atopic dermatitis, faster cyclosporine but longer lasting methotrexate [Google translation] (PharmaStar) - "Safety of treatment was overall reassuring, with a slightly higher number of non-serious adverse events in the methotrexate arm (407 vs 369), mainly nausea (43.1% vs 17.6%). 'We have seen this in clinical practice, but seeing this result in a trial gives us more confidence in discussing with parents,' commented session moderator Melinda Gooderham..."

Media quote

Miguel Regueiro, MD, on Care for the Hospitalized Patient With Ulcerative Colitis (HMP Global) - "In this video, Dr Regueiro discusses managing the patient hospitalized with severe ulcerative colitis."

Video

Subcutaneous Panniculitis Like T-Cell Lymphoma Presenting With HLH (SRM 2021) - P=NA, N=1; "SPTCL typically presents with erythematous painless plaques and nodules on the trunk and extremities. Systemic symptoms include fever, chills and weight loss. Cytopenia and elevated liver enzymes are common. The two types of SPTCL are alpha/beta and gamma/delta with the former being the less aggressive. STPCL presenting with HLH portends worse outcomes. Historically, many of these cases were treated with aggressive cytotoxic chemotherapy including cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (CHOP) based regimens; however, patients frequently relapse. There is no standardized treatment for SPTCL but previous studies suggest successful treatment with systemic steroids and cyclosporine."

Clinical data

Atopic dermatitis treatment advances on psoriasis research (DermatologyTimes) - "'It took decades for us to get from relatively primitive treatments of psoriasis to the very advanced perfected treatments that we currently have available, and we can clear almost everybody with these therapies. The advent of the biologics around the turn of the century has changed the treatment and management of inflammatory skin diseases forever,' says Mark Lebwohl M.D., FAAD...Cyclosporine worked well but it basically knocked out the whole immune system, Dr. Lebwohl says, making patients more susceptible to cancers, opportunistic infections, as well as a host of other side effects."

Media quote